Therapy for tuberculous meningitis

New England Journal of Medicine

Volumn 374, Issue 22, 2016, Pages 2187-

  Van Crevel, Reinout ^a   Ruslami, Rovina ^b   Aarnoutse, Rob ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PADJADJARAN UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; LEVOFLOXACIN; TUBERCULOSTATIC AGENT;

DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG MEGADOSE; HUMAN; LETTER; LUNG TUBERCULOSIS; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT RESPONSE; TUBERCULOUS MENINGITIS; VIET NAM; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; MALE; TUBERCULOSIS, MENINGEAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; LEVOFLOXACIN; MALE; RIFAMPIN; TUBERCULOSIS, MENINGEAL;

EID: 84973358456     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1602291     Document Type: Letter

References (4)

1. Heemskerk AD, Bang ND, Mai NTH, et al. Intensified anti-tuberculosis therapy in adults with tuberculous meningitis. N Engl J Med 2016; 374: 124-34.
2. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13: 27-35.
3. Te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 2015; 45: 496-503.
4. Boeree M, Hoelscher M. High-dose rifampin, SQ109 and moxifloxacin for treating TB: the PanACEA MAMS-TB trial. Presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, February 25, 2015. abstract.